Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
Essential Hypertension
About this trial
This is an interventional treatment trial for Essential Hypertension
Eligibility Criteria
Inclusion Criteria:
- Male or female of age ≥18 years;
- Diagnosed with mild-moderate essential hypertension;
- Participant has understood the study-required procedures, voluntarily signed informed consent.
Exclusion Criteria:
- Diagnosed with secondary hypertension, suspected grade 3 hypertension, acute hypertension, or at risk when current antihypertensive therapy discontinued;
- Suffered by severe heart disease within 6 months;
- Suffered by severe cerebrovascular disease within 6 months;
- Suffered by severe or malignant retinopathy;
- Out of controlled diabetes;
- History of malignant tumor;
- History of mental disorder;
- Subject is planning or in use of other antihypertensive drugs or other drugs may affect blood pressure during the trial;
- Alcohol or drug abuse;
- Pregnant, lactating women or subject is planning to pregnant within 6 months after the trial;
- Assessed by the investigators as unsuitable for participating in the study.
Sites / Locations
- Beijing HospitalRecruiting
- Beijing Anzhen Hospital, Capital Medical UniversityRecruiting
- Beijing Pinggu HospitalRecruiting
- Affiliated Hospital of Chongqing Three Gorges Medical CollegeRecruiting
- Lanzhou University Second HospitalRecruiting
- Guangdong Second Provincial General HospitalRecruiting
- Guangdong Provincial People's HospitalRecruiting
- Liuzhou people's HospitalRecruiting
- Hainan Third People's HospitalRecruiting
- Cangzhou Central HospitalRecruiting
- The First Hospital of Hebei Medical UniversityRecruiting
- The Third Hospital of Hebei Medical UniversityRecruiting
- Luoyang Third People's HospitalRecruiting
- Henan Provincial People's HospitalRecruiting
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRecruiting
- Tongji hospital,Tongji Medical college of HUSTRecruiting
- The Third Xiangya Hospital of Central South UniversityRecruiting
- XiangYa Hospital CentralSouth UniversityRecruiting
- The Second Xiangya Hospital of Central South UniversityRecruiting
- The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyRecruiting
- Chifeng Municipal HospitalRecruiting
- The Affiliated Hospital of Inner Mongolia Medical UniversityRecruiting
- The First Affiliated Hospital with Nanjing Medical UniversityRecruiting
- The Second Affiliated Hospital of Nanjing Medical UniversityRecruiting
- Suzhou Municipal HospitalRecruiting
- The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
- Xuzhou Central HospitalRecruiting
- Affiliated Hospital of Jiangsu UniversityRecruiting
- Shengjing Hospital of China Medical UniversityRecruiting
- The People's Hospital of Liaoning ProvinceRecruiting
- General Hospital of Ningxia Medical UniversityRecruiting
- The First People's Hospital of YinchuanRecruiting
- Ruijin Hospital, Shanghai Jiaotong University School Of MedicineRecruiting
- Yuncheng Central HospitalRecruiting
- West China Hospital,Sichuan UniversityRecruiting
- People's Hospital of TianjinRecruiting
- Tianjin Fourth Central HospitalRecruiting
- The First Affiliated Hospital of Xinjiang Medical UniversityRecruiting
- Affiliated Hangzhou First People's Hospital, Zhejiang University School of MedicineRecruiting
- Zhejiang Provincial people's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Stage 1 Arm A
Stage 1 Arm B
Stage 1 Arm C
Stage 1 Arm D
Stage 2 Arm A
Stage 2 Arm B
Stage 3
1 SPH3127 tablet,3 SPH3127 matching placebo tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
2 SPH3127 tablets,2 SPH3127 matching placebo tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
4 SPH3127 tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
4 SPH3127 matching placebo tablets, 1 valsartan capsule, once daily for 12 weeks.
2 SPH3127 tablets, 1 valsartan matching placebo capsule, once daily for 12 weeks.
2 SPH3127 matching placebo tablets, 1 valsartan capsule, once daily for 12 weeks.
2 SPH3127 tablets, once daily for 40 weeks.